See more : AgriMinco Corp. (ETPHF) Income Statement Analysis – Financial Results
Complete financial analysis of Psyence Group Inc. (PSYGF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Psyence Group Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- CAA Resources Limited (2112.HK) Income Statement Analysis – Financial Results
- Lar España Real Estate SOCIMI, S.A. (LRE.MC) Income Statement Analysis – Financial Results
- Sparinvest Japan Growth (SPIBJAKL.CO) Income Statement Analysis – Financial Results
- Xuan Wu Cloud Technology Holdings Limited (2392.HK) Income Statement Analysis – Financial Results
- JM Financial Limited (JMFINANCIL.NS) Income Statement Analysis – Financial Results
Psyence Group Inc. (PSYGF)
About Psyence Group Inc.
Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. The company is developing pharmaceutical preparations of psilocybin doses to help heal psychological trauma and diagnosable disorders, including anxiety, depression, post-traumatic stress disorder, and grief and bereavement. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 97.93K | 92.27K | 52.64K | 24.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -97.93K | -92.27K | -52.64K | -24.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.58M | 2.30M | 115.94K | 21.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.43M | 3.32M | 4.19M | 92.51K | 19.06K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 152.16K | 253.62K | 146.62K | 131.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.58M | 3.58M | 4.34M | 92.51K | 19.06K | 45.82K | 19.97K | 54.79K | 14.69K |
| Other Expenses | 0.00 | 5.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.16M | 5.97M | 4.51M | 92.51K | 19.06K | 45.82K | 19.97K | 54.79K | 14.69K |
| Cost & Expenses | 5.16M | 5.97M | 4.51M | 92.51K | 19.06K | 45.82K | 19.97K | 54.79K | 14.69K |
| Interest Income | 3.57K | 7.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 72.63K | 123.14K | 1.39K | 1.19K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 92.93K | 92.27K | 52.64K | 24.50K | 206.30K | 171.86K | 161.14K | 52.52K | 22.82K |
| EBITDA | -5.17M | -5.88M | -4.46M | -3.80M | -19.06K | -45.82K | -19.97K | -54.79K | -14.69K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.16M | -6.09M | -4.59M | -92.51K | -19.06K | -45.82K | -19.97K | -54.79K | -14.69K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -64.28M | -208.35K | -145.07K | -13.45M | 0.00 | 32.50K | 4.00 | 4.00 | -46.00 |
| Income Before Tax | -69.45M | -6.08M | -4.60M | -92.51K | -19.06K | -13.32K | -19.97K | -54.79K | -14.74K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -6.18K | -83.90K | -8.12M | -206.29K | -171.86K | -161.14K | -52.52K | -22.82K |
| Net Income | -69.45M | -6.08M | -4.60M | -92.51K | -19.06K | -13.32K | -19.97K | -54.79K | -14.74K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.52 | -0.07 | -0.05 | 0.00 | -0.01 | -0.02 | -0.04 | -0.11 | -0.03 |
| EPS Diluted | -0.52 | -0.07 | -0.05 | 0.00 | -0.01 | -0.02 | -0.04 | -0.11 | -0.03 |
| Weighted Avg Shares Out | 133.34M | 89.01M | 85.53M | 51.21M | 1.67M | 721.50K | 497.22K | 497.22K | 497.22K |
| Weighted Avg Shares Out (Dil) | 133.34M | 89.01M | 85.53M | 51.21M | 1.67M | 721.50K | 497.22K | 497.22K | 497.22K |
Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations
TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into an addendum to the previously announced debt-for-equity swap agreements (the "Debt Swap Agreements") with its NASDAQ-listed...
Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress
Independent valuation of PsyLabs values Psyence Biomed's stake at approximately $2 million, doubling in value Debt-for-equity swap with Psyence Group and Newcourt SPAC Sponsor results in strengthened balance sheet, with substantially reduced debt, heading into 2025 Psyence Biomed believes it...
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced an effective date for its previously-announced share consolidation. At its Annual General and Special Meeting of Shareholders, which was held...
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on...
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline data in the second half of 2025 NEW YORK, Oct....
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustment Disorder topline data in the second half of 2025 NEW YORK, Oct....
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
PsyLabs to exclusively supply Psyence Biomed with high purity, pharmaceutical grade psilocybin for its second development indication, Alcohol Use Disorder, as previously announced PsyLabs to exclusively supply Psyence Biomed with high purity, pharmaceutical grade psilocybin for its second development indication,...
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into a debt-for-equity swap agreement (the "Debt Swap Agreement") with its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ:...
Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company"), a developer of psilocybin-based therapeutics, today provided an update on its previously announced proposed acquisition of Clairvoyant Therapeutics, Inc. Following the completion...
Source: https://incomestatements.info
Category: Stock Reports